secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2025-05-28T23:59:59+00:00
Accession:  0001193805-25-000730
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic announces public offering of warrants and posts extended phase 2 CALLIPER data
--------------------------------------------------------------------------------

- Commenced underwritten public offering of pre-funded warrants and Series A (expire Dec 31, 2025) and Series B (5-year) warrants.
- Leerink Partners sole bookrunner; proceeds to fund clinical trials and general corporate purposes.
- Posted updated corporate presentation with extended data from phase 2 CALLIPER trial of vidofludimus calcium in progressive MS.
- Offering is subject to market conditions; no assurance of completion or final terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380525000730/0001193805-25-000730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380525000730/e664552_8k-immuniclaunch.htm
  HTML page:      https://secwatch.observer/filing/0001193805-25-000730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer